Daina Graybosch
Stock Analyst at Leerink Partners
(1.35)
# 3,557
Out of 5,174 analysts
99
Total ratings
42.65%
Success rate
-6.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Market Perform | $115 | $114.60 | +0.35% | 6 | Feb 24, 2026 | |
| IPSC Century Therapeutics | Downgrades: Market Perform | $7 → $2 | $2.37 | -15.61% | 5 | Nov 17, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.37 | +45.99% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $28 | $7.86 | +256.23% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $3.92 | +78.57% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $15.60 | -23.08% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $115.68 | +2.87% | 19 | Jan 13, 2025 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $4.38 | +356.62% | 8 | May 15, 2024 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $74.34 | -39.47% | 10 | Feb 24, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.15 | +769.57% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $21.41 | +77.49% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.51 | +77.38% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $88.41 | +153.37% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.18 | +1,276.15% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.82 | +1,964.36% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $2.09 | +330.62% | 4 | Feb 25, 2022 |
Arcellx
Feb 24, 2026
Downgrades: Market Perform
Price Target: $115
Current: $114.60
Upside: +0.35%
Century Therapeutics
Nov 17, 2025
Downgrades: Market Perform
Price Target: $7 → $2
Current: $2.37
Upside: -15.61%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.37
Upside: +45.99%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $28
Current: $7.86
Upside: +256.23%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $3.92
Upside: +78.57%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $15.60
Upside: -23.08%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $115.68
Upside: +2.87%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $4.38
Upside: +356.62%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $74.34
Upside: -39.47%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.15
Upside: +769.57%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $21.41
Upside: +77.49%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.51
Upside: +77.38%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $88.41
Upside: +153.37%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.18
Upside: +1,276.15%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.82
Upside: +1,964.36%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $2.09
Upside: +330.62%